Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Conditional Green Light for Allos Drug
June 7, 2004
| A version of this story appeared in
Volume 82, Issue 23
FDA has granted Allos Therapeutics conditional approval for RSR13 (efaproxiral), a drug that treats brain metastases originating from breast cancer. Approval is dependent on results of an ongoing Phase III clinical trial and inspection of Allos' manufacturing facility. The nod is a surprise, given that last month an FDA committee recommended against approval of RSR13, expressing concerns that a previous clinical test on a non-cancer-specific test group involved too few patients with breast cancer (C&EN, May 10, page 12). RSR13 is manufactured for Allos under contract by Hovione.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X